Back to Search Start Over

Latest insights in disease-modifying osteoarthritis drugs development.

Authors :
Shengfa Li
Peihua Cao
Tianyu Chen
Changhai Ding
Source :
Therapeutic Advances in Musculoskeletal Disease; Jan-Dec2023, Vol. 15, p1-24, 24p
Publication Year :
2023

Abstract

Osteoarthritis (OA) is a prevalent and severely debilitating disease with an unmet medical need. In order to alleviate OA symptoms or prevent structural progression of OA, new drugs, particularly disease-modifying osteoarthritis drugs (DMOADs), are required. Several drugs have been reported to attenuate cartilage loss or reduce subchondral bone lesions in OA and thus potentially be DMOADs. Most biologics (including interleukin-1 (IL-1) and tumor necrosis factor (TNF) inhibitors), sprifermin, and bisphosphonates failed to yield satisfactory results when treating OA. OA clinical heterogeneity is one of the primary reasons for the failure of these clinical trials, which can require different therapeutic approaches based on different phenotypes. This review describes the latest insights into the development of DMOADs. We summarize in this review the efficacy and safety profiles of various DMOADs targeting cartilage, synovitis, and subchondral bone endotypes in phase 2 and 3 clinical trials. To conclude, we summarize the reasons for clinical trial failures in OA and suggest possible solutions. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
1759720X
Volume :
15
Database :
Complementary Index
Journal :
Therapeutic Advances in Musculoskeletal Disease
Publication Type :
Academic Journal
Accession number :
175493817
Full Text :
https://doi.org/10.1177/1759720X231169839